Celcuity Inc. (CELC) · Sep 30, 2026 · Other events

Celcuity commercial launch begins for REVTORPYK, but sales proof comes later

U.S. launch — Commercial availability follows July 14 FDA approval and late-Q3 launch plan

Celcuity’s REVTORPYK launch is now live as planned for PIK3CA wild-type breast cancer, shifting the story from FDA approval to market uptake.

Celcuity is transitioning from a newly approved biotech into a commercial-stage company: REVTORPYK is its first FDA-approved product, while VIKTORIA-2 remains the main expansion program into first-line breast cancer treatment and the company is pursuing a broader PIK3CA-mutated label. This filing completes the regulatory-to-commercial handoff. REVTORPYK is now available in the United States for eligible patients with HR+/HER2- advanced breast cancer whose tumors lack a detected PIK3CA mutation after progression on endocrine therapy.

The event is important operationally, but not a surprise versus expectations. The FDA approval was already announced on July 14, 2026, and management had said commercial launch was targeted for late third-quarter 2026, so September 30 is essentially the expected launch window rather than a new regulatory win. 〔0〕 The business question now changes from approval risk to commercial adoption. The company has launched patient-support and reimbursement assistance, which may reduce access friction, but the filing provides no pricing, prescription, payer-coverage, or revenue data yet.

The product has a differentiated efficacy story, but commercialization still carries a tolerability burden. In the PIK3CA wild-type cohort, the company cites 76% and 67% reductions in the risk of progression or death for the triplet and doublet versus fulvestrant, respectively. However, the label highlights frequent stomatitis, rash, and increased fasting glucose, including Grade 3 stomatitis in 22% of triplet-treated patients and 12% of doublet-treated patients. Those adverse effects could influence physician selection, monitoring, and persistence even though the filing does not yet show real-world uptake.

The next value-creating expansion remains outside today’s approved population. Celcuity submitted an sNDA in August for PIK3CA-mutated disease; approval would broaden the addressable population beyond the current wild-type-only label. Bottom line: This is a meaningful execution milestone that puts Celcuity’s first product into the market, but it mainly confirms a previously telegraphed launch. The next proof point is commercial uptake, not another approval headline.

What to watch next

First commercial sales update, likely with next quarterly results

Original filing on SEC EDGAR

More Celcuity Inc. news

Celcuity commercial launch begins for REVTORPYK, but sales proof comes later | CELC Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.